An open-label, exploratory clinical trial to investigate the effects of Ginkgo biloba special extract EGb 761 on dopamine-induced executive cognitive functions and their neurophysiological correlation in subjects with mild cognitive deficits.
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2011
At a glance
- Drugs EGb 761 (Primary)
- Indications Mild cognitive impairment
- Focus Pharmacodynamics
- Sponsors Dr. Willmar Schwabe Group
- 01 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 14 Apr 2011 New trial record